PROMONTORY THERAPEUTICS
Forward thinking.
Promontory Therapeutics is a private, clinical-stage drug development company focusing on oncology therapeutics, running multiple clinical trials in the US and Europe.
The company’s clinical lead, PT-112, inhibits ribosome biogenesis which leads to immunogenic cell death (ICD) in cancer cells and a downstream anti-cancer immune response.
Promontory Therapeutics was a 2023 Prix Galien USA nominee for Best Startup.
Our mission is to lead the development of immunogenic small molecules in cancer care.
A notable history.
Promontory Therapeutics was founded by two entrepreneurs in 2010, with headquarters located in New York City. Since that time, we have built inter-disciplinary teams — both internally and externally — and conducted collaborations globally. We are an independent and privately funded company, and hold the exclusive global license to a novel family of compounds that includes our lead agent, PT-112. Our Research and Development efforts comprise university and pharmaceutical industry collaborators in the US and Europe; along with development stage manufacturing in both the US and Europe.
We are currently in Phase 2 clinical development with two ongoing studies in solid tumors and have completed a Phase 1 study in hematological oncology. Notably, we have received Orphan Drug designation for Thymoma and Multiple Myeloma.
Our partners.
Over the years, we have developed collaborations with pharmaceutical partners and world-class investigators from universities and leading clinical research sites globally.
CLINICAL SITES
Alliances with outstanding institutions worldwide.
University of Texas MD Anderson Cancer Center
The Mayo Clinic
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Dana Farber Cancer Institute
Weill Cornell Medical College
